Two major drugmakers halted late‑stage muscle‑growth and muscle‑preserving programs after trial data failed to show consistent benefit. Roche announced it would stop development of emugrobart after a key study showed the drug did not reliably improve muscle growth and motor outcomes. Separately, Genentech pulled an antibody candidate when it failed to boost muscle in targeted rare disease indications. Both decisions raise questions about the translatability of muscle‑anabolic approaches in genetic and rare muscle disorders and have direct implications for ongoing obesity trials that rely on related mechanisms. The moves will shift internal portfolios and may reshape investment in muscle‑preserving strategies across oncology and metabolic programs. Companies cited patient safety and lack of consistent efficacy as drivers for halting development; the decisions will also affect trial participants and regulatory timelines for related programs.